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1. Introduction 
Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the lymphocytic 
infiltration of salivary and lacrymal glands leading to xerostomia and keratoconjunctivitis 
sicca (KCS). The prevalence of SS is variable but recent studies have estimated it to be between 
0.1-0.6%(Goransson et al., 2011; Trontzas & Andrianakos, 2005). As such, SS occurs in middle-
aged patients with a high female predominance of 9 to 1 (Fox, 2005). SS is classified either as 
primary (pSS) when occurring alone or secondary (sSS) to other autoimmune diseases such as 
rheumatoid arthritis or systemic lupus erythematosus. Besides the involvement of exocrine 
glands entailing the classical sicca syndrome, systemic manifestations resulting from the 
lymphocytic infiltration of organs can be present in up to 20% of cases. There are actually no 
specific diagnostic criteria for SS, but for clinical studies and teaching purposes, SS is classified 
according to the American-European classification criteria, which include subjective and 
objective criteria of xerostomia and KCS as well as the presence of autoimmune antibodies and 
histopathological salivary gland involvement. Because of the lack of a “gold standard” for SS, 
the standard of reference being actually used is clinical diagnosis made by an experienced 
clinician. The lack of specific diagnostic tests combined with the high frequency of sicca 
symptoms in the general population makes the diagnosis of SS even more complicated. This 
holds true especially in early disease where the symptoms and signs are usually mild and 
might explain the time delay for the diagnosis of SS. The importance of making the diagnosis 
of pSS is cardinal because of the increased risk of developing lymphoma and serious systemic 
complications. In an endeavor to increase the likelihood of diagnosis of SS, newer diagnostic 
tools have been devised such as ultrasound sonography of salivary glands, magnetic 
resonance imaging of parotid glands as well as epigenetic biomarkers. 
2. Pathophysiology of Sjögren’s syndrome 
Even if tremendous progress in the field of research has been made to unveil the different 
mechanistic processes underlying the development of SS, the initial triggering events of the 
disease have yet to be unearthed. Central to the pathophysiology of SS is chronic perpetual 
stimulation of the autoimmune system. Both B and T cells are implicated in the pathogenesis 
of the SS, even though the mechanisms underlying humoral and cellular abnormalities are 
not yet known (Delaleu et al., 2008; Mariette & Gottenberg, 2010). 
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It is actually believed that a combination of several factors is responsible for triggering 
disease initiation and perpetuation. In genetically predisposed individuals, psychological or 
physical stress and hormonal factors can lead to the activation of epithelial cells and to the 
up regulation of toll-like receptors. Initiation of disease is promoted by altered glandular 
architecture such as extracellular matrix modification favoring infiltration by cytokines, 
chemokines and lymphocytes. Up regulation of toll-like receptors leads to T cell activation 
and ensuing secretion of pro-inflammatory cytokines. Furthermore, activated epithelial cells 
not only can act as antigen presenting cells leading to the activation of T and B cells, but also 
activate dendritic cells through up regulation of proapoptotic molecules harboring the 
formation of exosomes and thereby also further activating B cells. In advanced stages of the 
disease process, enhanced B-cell activating factor (BAFF) activation and secretion leads to 
disproportionate activation of B cells thereby favoring aberrant lymphocyte homing, 
increased glandular destruction, formation of germinal centers and ensuing lymphoma 
(Figure 1)(Manoussakis & Kapsogeorgou, 2010). 
3. Clinical characteristics of SS 
The most frequent symptoms of SS include the triad of fatigue, polyarthralgia and sicca 
symptoms. Because of the higher frequency of these symptoms in the general population, 
many patients are often diagnosed as having fibromyalgia. 
 
Fig. 1. Mechanisms underscoring the pathogenesis of SS. In the setting of appropriate 
genetic background, the conjuncture of viral aggression, hormones and environmental 
factors is thought to initiate epithelium activation which in turn, leads to T cell activation 
and hence pro-inflammatory cytokines secretion thereby further perpetuating activation of 
epithelial cells. This results in exosomes formation, dendritic cells (DC) activation and 
secretion of type I IFN and BAFF leading to B cell stimulation and proliferation, leading to 
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aberrant lymphocyte homing, T cell cytotoxicity, apoptosis and autoantibodies formation 
and further glandular destruction. BAFF: B-cell activating factor; Dc dendritic cells; IFN: 
interferon; IL-1: interleukin-1; TNF-: tumor necrosis factor . 
The most prominent clinical feature of SS is the sicca syndrome of xerostomia and 
keratoconjunctivitis sicca (KCS) resulting from lymphocytic infiltration of salivary and 
lachrymal glands. The sicca syndrome is often extended to other organs and might result in 
skin dryness, vaginal dryness resulting in dyspareunia, and respiratory tract dryness. 
3.1 Xerostomia 
More than 90% of patients with SS complain of symptoms resulting from functional 
alteration of salivary glands. Patients often complain of unpleasant taste, difficulties in 
eating dry food, the need to drink more water or difficulties in controlling dentures. In the 
early stages of SS, the mouth may appear to be moist, but with disease progression, pooling 
of saliva in the floor of the mouth disappears, thereby unveiling the lines of contact between 
frothy saliva and oral soft tissue. With disease progression and especially in advanced 
stages of SS, the oral mucosa becomes extremely dry and tends to form wrinkles. The 
surface of the tongue becomes red and lobulated with partial or complete depapillation. The 
symptoms of xerostomia extend to a painful syndrome with the sensation of permanent 
burns, soreness, taste alteration, “clicking quality” in the speech of patients with SS, tongue 
fissuring, dysphagia and angular cheilitis. Gross accumulation of plaque might prevail. 
Infections by staphylococcus aureus or pneumococcus can result in acute sialadenitis. With 
further disease progression, teeth decay, periodontal infections, increased incidence of 
candidiasis infections and ultimately loss of teeth are possible complications (Fox, 2005, 
Kassan & Moutsopoulos, 2004). 
3.2 Keratoconjunctivitis sicca 
Ocular dryness in SS, also known as keratoconjunctivitis sicca (KCS), is often less prominent 
than xerostomia. A detailed anamnestic investigation is necessary to detect ocular dryness 
symptoms. The main complaint of KCS is foreign-body sensation, but other symptoms such 
as grittiness, thick rope like secretions at the inner canthus, photosensitivity, burns, and 
sensation of having a veil before the eyes, absence of tears after irritation or emotion are all 
frequent features of KCS. Ocular dryness is due to the lymphocytic infiltration of lacrimal 
glands leading to diminished lacrimal flow and tear composition, thereby altering corneal 
and conjunctival epithelia, characterizing the known condition of keratoconjunctivitis sicca 
(KCS). In more severe disease, functional disability with visual impairment occurs. 
Complications of KCS include corneal ulcerations that can lead to perforations and 
iridocyclitis (Fox, 2005). 
3.3 Systemic manifestations  
3.3.1 Musculoskeletal manifestations 
Approximately 70% of patients with SS complain of articular manifestations. The main 
articular features are predominantly arthralgia while arthritis is less frequent (Fauchais et 
al., 2010). Polyarthralgia is relapsing and remitting. Symmetric, non-erosive, polyarthritis 
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affecting the small joints can also be observed and can even precede the sicca syndrome. The 
frequency of arthritis in SS has been shown to be nearing 17%. More recently, it has been 
observed that subclinical synovitis might be more important with the use of 
ultrasonography and that the frequency of arthritis is around 25%(Iagnocco et al., 2010). 
Myalgias are also a frequent feature, accompanied with asthenia, fatigue and muscle 
tenderness, realizing a fibromyalgia-like syndrome (Mavragani & Moutsopoulos, 2010).  
3.3.2 Respiratory manifestations 
Diminished secretion from nasal epithelial cells results in nasal crusting, epistaxis and 
recurrent sinusitis. Due to xerotrachea, patients complain of a dry non-productive cough 
and dyspnea. In more than 50% of SS patients, dry irritating cough was present without any 
radiographic abnormalities. Bronchial hyperreactivity due to lymphocytic infiltration might 
result in small airways obstruction and contribute to the development of cysts and bullae 
(Parke, 2008). 
Interstitial lung disease (ILD) is a classic feature of SS. The clinical manifestations include 
cough, dyspnea on exertion, bilateral pulmonary infiltrates on plain chest radiographs and 
other abnormalities on computer tomography scanner such as wall thickening at the 
segmental bronchi. With disease progression, fibrosis and neutrophilic alveolitis are present 
(Parambil et al., 2006). 
Lymphocytic interstitial pneumonia (LIP), previously considered as a hallmark of lung 
involvement for SS, forms part of the spectrum of ILD. As such, LIP is the corollary of 
bronchus associated lymphoid tissue proliferation (BALT). LIP is found in approximately 
1% of patients who have SS. Even if LIP is steroid- responsive, approximately 5% of patients 
who have LIP progress to develop overt lymphoma, and the 5-year mortality for these 
patients can rise up to 50% (Parambil et al., 2006). 
Patients with SS are at increased risk of developing lymphoma, usually low grade MALT 
lymphoma. Up regulation of the proliferation of BALT might result into malignant 
transformation with the development of primary pulmonary lymphoma. Typically these 
patients present with few clinical symptoms such as cough, mild weight loss, and dyspnea 
on exertion. Strikingly, these minimal symptoms are unparalleled by the severe 
radiographic changes encompassing micronodules, nodular bilateral and confluent 
infiltrates, thickening of bronchial walls, air bronchograms and ground glass images (Parke, 
2008). 
Pulmonary hypertension is a very rare finding in patients with SS. Only 17 cases have been 
documented in the literature. Prolonged vasospasm and vasculature remodeling have been 
assigned to contribute to the development of this pathology (Launay et al., 2007). 
3.3.3 Renal manifestations 
Tubulointerstitial nephritis is the most predominant clinical manifestation of renal 
involvement in SS. This is characterized by distal tubular acidosis (type 1) and less 
frequently proximal tubular acidosis (type II) (Fanconi syndrome) (Bossini et al., 2001). 
Renal biopsy typically reveals interstitial lymphocytic infiltration. Most of the patients 
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present with hyposthenuria and hypokalemic, hyperchloremic distal renal tubular acidosis 
reflecting interstitial infiltration and destruction by lymphocytes. Distal tubular acidosis 
might be clinically silent but significant untreated renal tubular acidosis can lead to renal 
stones, nephrocalcinosis, and compromised renal function. 
Glomerulonephritis is very rare in SS. When it occurs it is often due to cryoglobulinemia. 
Histopathological examination of the kidney shows proliferative glomerulonephritis 
(Aasarod et al., 2000). 
3.3.4 Cutaneous features 
Besides the classical features of dry skin, other skin manifestations might also be present. 
Purpura might be present in up to 30% of patients presenting as petechiae frequently localized 
on the lower limbs. They follow a remitting and relapsing course and are associated with 
worse prognosis of SS. Vasculitis is detected in approximately 10% of patients with pSS 
(Ramos-Casals et al., 2004). It is characterized by a high predominance of leucocytoclastic 
vasculitis, with life threatening vasculitis being related to cryoglobulinemia. These symptoms 
usually resolve with corticosteroids. Other manifestations of vasculitis in SS include recurrent 
urticaria and skin ulcerations. Cryoglobulinemia can be present in SS patients, and can present 
with a clinical picture of purpura. Other skin manifestations include erythema nodosa, vitiligo, 
and digital ulcers (Kittridge et al; 2011). One of the most characteristic non-vasculitic 
cutaneous manifestations of SS are polycyclic, photosensitive cutaneous lesions. These lesions 
are clinically similar to those observed in cutaneous lupus erythematosus. 
3.3.5 Neurological manifestations  
The spectrum of neurological disorders associated with SS is broad ranging from peripheral 
neuropathy to central nervous involvement. The frequency of neurological involvement in 
SS is relatively low (<5%). In up to 80% of cases, neurological involvement might even 
precede the diagnosis of SS (Segal et al., 2008). 
3.3.5.1 Central nervous system involvement 
 CNS involvement in SS is very much identical to that of systemic lupus erythematosus. As 
such, the clinical manifestations include hemiparesis, cranial neuropathy and more often 
optic nerve neuropathy, brainstem and cerebellar disorders, movement disorders, epilepsia. 
Spinal cord syndromes encompass transverse myelitis, Brown-Sequard syndrome and 
progressive myelitis. Due to the presence of optic neuropathy and myelitis, a diagnosis of 
multiple sclerosis is often evoked. Furthermore, MRI imaging discloses hyperintense lesions 
in the white matter. Neuromyelitis optica (also known as Devic’s disease) is often associated 
with SS and is characterized by recurrent episodes of myelitis and optic neuropathy. 
The clinical features of neuropsychiatric syndrome include often cognition, anxiety, mood 
changes, and depression and sleep disorders (Lafitte et al., 2001). 
3.3.5.2 Peripheral nervous system involvement 
Peripheral neuropathy is much more frequent than CNS involvement ranging up to 30% of 
cases. In most of the cases (93%), peripheral neuropathy precedes the diagnosis of SS. 
Sensory neuronopathy is considered to be distinctive of SS but sensorimotor neuropathy, 
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sensory neuropathy, autonomic neuropathy, monoeuritis multiplex are amongst other 
features of peripheral nervous system involvement.  
Trigeminal neuropathy is one of the most common vignettes of neurological involvement in 
SS, which can be either uni or bilateral, but, in essence, is a pure form of sensory 
neuropathy. It is characterized by painful paresthesias of the face and hypoesthesia (Lafitte 
et al., 2001). 
3.3.6 Gastrointestinal features 
The manifestations of gastrointestinal tract are not very specific and include esophageal 
dysmotility and gastro-intestinal reflux. Patients often complain of dysphagia, nausea and 
epigastric pain. Subclinical pancreatic involvement is present in approximately 25% of cases. 
There are no specific liver abnormalities, which can be attributed to SS, but autoimmune 
hepatitis and primary biliary cirrhosis can be associated diseases (Mavragani and 
Moutsopoulos, 2010, Fox, 2005). 
3.3.7 Thyroid disease 
Hashimoto’s thyroiditis is a commonly present in SS. Thirty to fifty percent of patients with 
SS has anti-thyroid antibodies and elevated basal thyroid stimulating hormone levels 
(Ramos-Casals et al., 2000). 
3.3.8 Laboratory manifestations 
3.3.8.1 Non-specific laboratory manifestations 
Several hematological features such as anemia, leucopenia and thrombopenia can exist. 
Mild anemia of chronic disease is present in up to 25% of cases but might also result from 
hemodilution due to polyclonal hypergammaglobulinemia (Tzioufas & Voulgarelis, 2007). 
Leucopenia < 4000/mm3 is present in 30% of cases. Hypergammaglobulinemia is most 
frequent occurring in 80% of cases. In certain cases of major hypergammaglobulinemia, a 
hyperviscosity syndrome can be present (Fox RI, 2005). 
Erythrocyte sedimentation rate is often elevated because of polyclonal 
hypergammaglobulinemia. In most of the cases serum IgG are increased, while IgA and IgM 
are normal. If hypogammaglobulinemia exists, lymphoma should be excluded. In 10% of 
cases, a monoclonal protein is observed. Type II and type III cryoglobulinemia are present in 
5% of SS patients (Ramos-Casals et al., 1998). 2-microglobulinemia is significantly 
increased in the sera of patients suffering from SS. There is significant positive correlation 
between 2-microglobulinemia levels and disease activity (Skopouli et al., 2000, Gottenberg 
et al., 2005, Theander et al., 2006, Pertovaara & Korpela, 2011). Serum free light chains have 
been found to be increased in SS and correlate with disease activity (Gottenberg et al., 2007). 
Rheumatoid factor is found in 50% of cases in primary SS. 
3.3.8.2 Autoimmune laboratory manifestations 
Anti nuclear antibodies are frequently observed in the serum of SS patients. Anti-SSA 
autoantibodies are found in 30 to 50% of sera of patients with SS, while anti-SSB 
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autoantibodies are found in 20 to 30% of cases. In the majority of cases the presence of anti-
SSB autoantibodies is associated with the presence of anti-SSA antibodies. Extraglandular 
manifestations are usually predominant in patients presenting with these autoantibodies. 
Antibodies against -fodrin have been exclusively (>95%) found in the sera of SS patients in 
only one German study while other studies have shown a relatively low sensitivity of 30% 
(Willeke et al., 2007). Because of the absence of adequate commercially available kit, this test 
is not routinely performed (Witte, 2005). Recently, new autoantibodies directed against the 
muscarinic receptors M3 and the proteasomes have been described in patients with SS (Feist 
et al., 1999, He et al., 2011). Abnormalities complement C4 levels are often associated with 
the presence of cryoglobulinemia. 
3.3.9 Lymphoma  
Patients with SS have a 20 to 40-fold risk of developing non-Hodgkin lymphoma (NHL) as 
compared to the general population (Voulgarelis et al., 1999,Theander et al., 2006, 
Voulgarelis & Moutsopoulos, 2008). NHL has a prevalence of about 4% in SS and occurs 
classically following a median of 7.5 years after its initial diagnosis (Skopouli et al., 2000). 
Various histologic subtypes of NHL for patients with SS have been described, including 
follicle center lymphomas, lymphoplasmacytoid lymphomas, diffuse large B-cell 
lymphomas (DLBCLs), and – in particular – mucosa-associated lymphoid tissue (MALT) 
lymphomas. 
Extranodal marginal zone (MZ) B-cell lymphomas of the MALT type are the most frequent 
type of lymphomas in SS. Generally, MALT lymphomas follow an indolent course, 
frequently located in both mucosal and non mucosal extranodal sites, a common 
denominator being the presence of epithelium suggesting that the intrinsic feature of these 
cells is homing to epithelia rather than mucosa (Pelstring et al., 1999). Most of the organs in 
which MALT lymphomas arise are devoid of lymphoid tissue, and in the majority of cases 
MALT acquisition precedes lymphoma development. All of these lymphomas appear to 
derive from neoplastic transformation of MZ B lymphocytes in spite of the fact that they are 
associated with several infectious agents or autoimmune disorders such as SS or Hashimoto 
thyroiditis (Royer et al., 1997). The histological features of MALT lymphoma closely mimic 
those of Peyer's patch lymphoid tissue and include: (1) reactive lymphoid follicles, with or 
without colonization by neoplastic cells; (2) MZ and/or monocytoid B-cells (centrocyte-like 
cells) that infiltrate the overlying epithelium (lymphoepithelial lesions); (3) small  
B-lymphocytes; and (4) plasma cells, which might or not be of malignant origin. 
In most cases MZ lymphomas of the MALT type in patients with SS are either primary low-
grade or localized (stage I and II) with extranodal manifestations. The clinical course of the 
majority of NHL lymphoma is indolent and the clinical characteristics include small tumor 
burden and good performance status.  The salivary glands are the most commonly affected 
site, but other extranodal sites – such as the stomach, nasopharynx, skin, liver, kidney, and 
lung – can also be involved. Twenty per cent of patients display involvement of more than 
one extranodal site at diagnosis, indicating that these lymphomas migrate preferentially to 
other mucosal sites, thereby emphasizing the importance for complete staging procedures in 
patients with SS with MALT lymphomas. Even if the lymphoma rarely involves peripheral 
lymph nodes, it frequently disseminates to locoregional lymph nodes. Presenting symptoms 
are the result of major gland enlargement, mainly bilateral parotid gland enlargement. The 
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clinical picture in these patients is not characterized by the classical presence of B symptoms 
(fever, night sweats and weight loss) and bone marrow infiltration is rare. However, in 
disseminated disease more than one extranodal site is usually involved. The clinical and 
biological factors heralding imminent lymphoma are low C4/C3 levels, palpable purpura, 
high 2-microglobulin levels, CD4 lymphocytopenia, parotid gland swelling and persistent 
enlargement and hypocaptation on salivary scintigraphy, presence of germinal centers in 
salivary glands, mixed monoclonal cryoglobulinemia, leg ulcers, peripheral neuropathy, 
splenomegaly and the presence of serum or urine monoclonal bands (Theander et al., 2006, 
Skopouli et al., 2000). More recently, it has been shown that hypocomplementemia and 
lymphocytopenia at diagnosis of SS were the strongest predictors of developing lymphoma 
(Solans-laqué et al., 2011). Consequently, the presence of NHL should be considered at the 
initial assessment of a patient with SS depicting clinical signs such as significant 
enlargement of the salivary glands, lymphadenopathy, splenomegaly, skin vasculitis, and 
peripheral neuropathy. 
In certain cases, lymphomas in patients with SS might progress towards a less differentiated 
cell type. The transition from benign chronic lymphoepithelial sialadenitis (LESA) to 
indolent extranodal MZ lymphomas of the MALT type and – possibly – to high-grade 
lymphoma (e.g. DLBCL), is generally considered to represent a multi-step, antigen-driven 
process. Transformation of MALT lymphoma to DLBCL is heralded by the emergence of an 
increased number of transformed blasts that form sheets or clusters and finally form a 
confluence effacing the preceding MALT lymphoma. Most high-grade lymphomas in 
salivary glands are DLBCLs. It is not known how many of the DLBCLs arise from pre-
existing MALT lymphomas and how many are of nodal type or represent transformation of 
follicular lymphomas. There are several lines of evidence from immunohistochemical, 
karyotypic, and genotypic studies that the supervening large-cell lymphomas arise from the 
same clone as the low-grade lymphomas. As such, it can be implied that most of the high-
grade lymphomas could represent a blastic variance of either MZ B-cell or follicular-center-
cell lymphomas.  The clinical manifestation during transformation to high-grade lymphoma 
is purported by further nodal and extranodal dissemination. Whilst MALT lymphoma in 
patients with SS carries a good prognosis, the histologic transformation to high grade 
lymphoma is not with a median overall survival estimated to be only 1.8 years (Voulgarelis 
et al., 1999). 
In summary, NHLs in SS are dichotomized into two categories: the first relating to the 
majority of patients who develop an indolent extranodal MZ lymphoma and the second, less 
frequent, relating to those developing high-grade aggressive lymphomas, such as de novo or 
secondary DLBCLs. 
4. Diagnostic tools for SS 
4.1 Sialometry and sialochemistry 
Salivary flow rates can be measured clinically for whole saliva or for separate secretions 
from the parotid or submandibular and sublingual glands, with or without stimulation. 
Patients with clinically overt SS have reduced flow. However, flow rates depend on many 
factors, such as age, sex, medication, and time of day. For analytical purposes, whole saliva 
is of limited value as it detects neither dysfunction of any of the separate salivary glands nor 
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gland specific sialochemical changes (Kalk et al., 2001). In patients with SS, lower 
submandibular/sublingual flow rates were observed as compared to controls. Measuring 
submandibular/sublingual flow rates may contribute to an early diagnosis of SS. In 
contrast, parotid flow rates are decreased in SS and Non-SS sicca patients. Sialochemistry of 
collected glandular saliva samples may show several characteristic changes in electrolytes 
and proteins (enzymes) in SS (Van der Reijden Kwaak et al., 1996). The Na+ concentration 
level in the parotid glandular saliva is six fold higher in SS patients as compared to non-SS 
and healthy volunteers (Kalk et al., 2001). 
4.2 Sialography 
Sialography consists in the radiography of the salivary glands and its associated ducts 
following the injection of a contrast radiopaque substance. This technique enables the 
assessment of the anatomical changes occurring in the salivary gland ductal system. The 
procedure of sialography is indeed invasive in that it necessitates the cannulation of the 
salivary gland and ductal system being evaluated. Two types of radiocontrast substance can 
be utilized: fat soluble and water-soluble compounds. Water-soluble contrast media are 
usually preferred in that they induce less localized inflammation in contrast to fat-soluble 
compounds, which provide better radiographic imaging and contrast but can entail chronic 
inflammatory changes if leakage of the product occurs. 
The changes observed in SS consist of salivary glands duct dilatations, duct strictures, 
sialectasis and occasionally peripheral duct narrowing. The sensitivity of parotid 
sialography ranges from 48%to 86% and specificity values stretching from 61% to 100%. 
4.3 Salivary gland scintigraphy 
Salivary scintigraphy is a valid and non-invasive procedure to assess the involvement of 
salivary glands in patients with xerostomia. After intravenous 99mTc-sodium pertechnetate 
administration, sequential images of the head, on anterior projection, are acquired during a 
variable time interval, usually between 20 and 40 minutes. The images are then stored and 
glandular regions of interest (ROI) and a background ROI, usually in the skull, are manually 
drawn. Computer software generates time–activity curves for each major salivary gland. 
Time–activity curves are divided in two phases: the uptake phase, corresponding to the 
accumulation of the tracer by the glandular parenchyma, the duration of which depends on 
the protocol; and the excretion phase, initiated by the administration of a salivary stimulus, 
usually lemon juice, which corresponds to the tracer elimination through the oral cavity, 
providing information on the patency of salivary ducts and the overall functional integrity 
of the system (Vinagre et al., 2009). Abnormal salivary scintigraphy findings include 
delayed uptake, reduced concentration and/or delayed uptake of the tracer, according to 
the method proposed by Schall (Schall et al., 1971). According to the Schall classification, 
salivary gland functional impairment is classified into four grades, following the intensity of 
uptake and activity present at the mouth after administration of the salivary stimulus; grade 
1 classified as normal tracer uptake and grade 4 as complete absence of uptake and mouth 
activity. This widely diffused classification is considered the standard method for salivary 
scintigram interpretation but is observer dependent. The overall sensitivity and specificity of 
salivary scintigraphy is 54% and 98% respectively (Kohn et al., 1992). The most common and 
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early scintigraphic abnormality observed in SS is the impairment of excretion, followed by a 
decrease in tracer accumulation, reflecting glandular parenchyma destruction. The 
preferential involvement of the submandibular glands in SS and the decrease of non-
stimulated salivary secretion by these glands are correlated to the degree of xerostomia. 
Recently, quantitative evaluation of salivary gland dysfunction has been developed and 
there is data supporting the fact that quantitative salivary scintigraphy can detect minimal 
salivary glands abnormalities, detecting as low as 25% of glandular destruction and is 
therefore important to identify glandular dysfunction in early SS (Bohuslavizki et al., 1995). 
4.4 Tear function tests 
4.4.1 Schirmer’s test 
The Schirmer’s test consists in assessing the function of the lachrymal gland. The Schirmer’s 
I test consists in measuring the amount of wetting on a strip of filter paper placed in the 
lower eyelid over 5 minutes. In the normal non-anesthetized eye, at least 15mm of wetting is 
expected in patients younger than 40 years old, and at least 10mm of wetting is expected in 
elderly patients. If no anesthetic is placed onto the eye, the expected wetting of the filter 
strip sums up to at least 10 mm in a healthy patient younger than 40 years and at least 5 mm 
in a patient older than 40years. The schirmer’s I test is considered to be anormal if it results 
in less than 5 mm of wetting confirms the clinical diagnosis of dry eye syndrome. A result of 
6–10 mm of wetting suggests a dry eye problem (Lemp, 2000). The Schirmer’s II test is quite 
similar to the I test, the difference being that a cotton swab is used to trigger the tear reflex 
inside the nose. 
The phenol red thread test has been developed to obviate the disadvantages of Schirmer's 
test by eliminating the need for anesthesia. Three millimeters of a fine dye-impregnated 75 
mm cotton thread is placed under the lateral one fifth of the inferior palpebral lid margin for 
15 seconds; alkalinity changes its color to bright orange from tear contact. Direct stimulation 
of the nasociliary nerve through irritation of the nasopharynx confirms the presence or 
absence of reflex tearing. More recently the combination of the phenol red thread test with 
the Schirmer’s test was found to be highly predictive of severe ocular sicca syndrome (De 
Monchy et al., 2011). 
Hyperosmolarity is a common endpoint for all dry eye syndromes and its measurement is a 
sensitive, but not specific, test since it does not distinguish between tear-deficient and tear-
sufficient dry eye. Other rarely performed tests for reduced tear function include 
fluorophotometry for decreased protein content, lysozyme levels, ocular ferning, impression 
cytology, and lactoferrin assays. 
4.4.2 Diagnostic dye evaluation 
Fluorescein is a large molecule unable to traverse normal corneal epithelial tight junctions. 
In advanced dry eye syndrome, these junctions are disrupted, allowing characteristic diffuse 
subepithelial or punctate staining. Rose Bengal, a derivative of fluorescein, in a 1% solution 
or impregnated strips stains devitalized epithelial cells. Alternatively, lissamine green stains 
for cell death or degeneration, as well as cell-to-cell junction disruption, but does not irritate 
the eye. Van Bijsterveld created a grading scale for rose Bengal dye that divides the ocular 
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surface into three zones: nasal bulbar conjunctiva, cornea, and temporal bulbar conjunctiva, 
each graded 0–3 (0, none; 3, confluent staining) (Van Bijsterveld, 1969). A maximum of nine 
can be obtained and a score ≥ 4 is considered as positive test. The Van Bijsterveld score is the 
most specific ocular test for evaluation of SS (Kalk et al., 2002). 
4.4.3 Tear film stability 
Tear film instability can be due to either tear deficiency or evaporative dry eye syndrome. In 
tear breakup time, fluorescein dye is instilled and the time interval is measured between a 
complete blink to the first appearance of a dry spot in the precorneal tear film. As such, tear 
breakup time shorter than the blink interval of 5 seconds could imply ocular surface damage 
while very short tear breakup time (less than 2 seconds) is suggestive of KCS. 
4.5 Salivary gland biopsy 
The histopathology of labial salivary glands is a key feature in the diagnosis of SS. A widely 
accepted criterion for histopathological confirmation of SS is focal lymphocytic sialadenitis 
of the labial salivary glands. Minor labial salivary glands biopsy is performed by midline 
incision (of about 1.5-2.0 cm) of lower lip under local anesthesia. Four to six lobules of minor 
salivary glands are harvested because of prominent variation in the degree of inflammatory 
and destructive involvement of salivary glands and lobes (Greenspan et al., 1974) 
Assessment of inflammatory infiltrates in the salivary gland is based on the number of foci 
present in the glands, classified as the focus score (FS) (Greenspan et al., 1974). The FS is the 
number of foci per 4mm2 of salivary gland section. The FS represents an extension of the 
grade 4 classification of labial salivary gland biopsies of Chisholm and Masson (Table 1). 
The FS is graded from 0 to 12, with a FS of 0 representing the absence of one focus, while a 
FS of 12 represent those specimens where the foci are so numerous that they have become 
confluent. A FS  1 is considered as positive for the diagnosis of SS. It has to be underlined 
that a FS  1 can also be observed in other systemic autoimmune diseases such as RA, SLE 
and in 5-10% of healthy subjects thereby reducing its specificity for SS (Bodeutsch et al., 
1992, Lindahl & Hedfors, 1989; Lindahl et al., 1989). Moreover, the sensitivity of FS is 
reduced in smokers and in patients taking corticosteroids ((Manthorpe et al., 2000), 
(Zandbelt et al., 2001). The combination of FS  1 and immunological staining for IgA has 
been shown to increase the diagnostic specificity for SS (Zandbelt et al., 2002). Indeed, the 
presence of a Fs  1 and quantitative immunohistogical staining of IgA < 70%, had greater 
sensitivity and specificity than the FS alone. 
 
Grade Lymphocytes and plasma cells per 4mm2 of gland tissue 
0 Absent 
1 Slight infiltrate 
2 Moderate infiltrate or less than 50 lymphocytes/4mm2 
3 One focus per 4mm2 
4 More than one focus per 4 mm2 
Table 1. represents the grading of labial salivary gland biopsies according to the 
classification by Chisholm and Mason (Chisholm & Mason, 1968). 
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Parotid gland biopsy can also be an adjunct diagnostic tool for the diagnosis of SS. Previous 
prospective studies have shown that the performance of minor salivary gland biopsy is 
comparable to parotid gland biopsy, which explains why parotid gland biopsy is less often 
performed (Pijpe et al. 2007,Wise et al., 1988).  As such, incisional parotid biopsy is not 
performed because of the fear of facial nerve injury, sialoceles and fistulae. One of the 
advantages of parotid gland biopsy over labial salivary gland biopsy is that 
lymphoepithelial islands or lymphoepithelial lesions (LELs) are often observed in parotid 
gland tissue of SS patients. These LELs, a characteristic histological feature of the major 
salivary glands in SS develop as a result of hyperplasia of ductal basal cells within a 
lymphocytic infiltrate. In addition, well-formed lymphoid follicles or germinal centers, often 
adjacent to ductal epithelium, can be found in the major salivary glands (Jordan & Speight, 
1996). 
4.6 New diagnostic tools in SS 
Ultrasonography is an inexpensive, noninvasive technique that is used to detect several 
abnormalities in the major salivary glands. The normal parotid gland appears 
homogeneous, with increased echogenicity relative to adjacent muscle on ultrasonography. 
Ultrasonography of salivary gland is a useful tool to detect anatomical changes in the 
parotid and submandibular glands, with similar diagnostic ability to sialography. 
Hypoechoic or anechoic areas are believed to represent lymphocytic infiltration, damaged 
salivary parenchyma, and dilated ducts. As the disease progresses, numerous cystic spaces 
appear, which most likely reflect progressive glandular destruction and prominent intra-
glandular sialectasis (Madani & Beale, 2006). Moreover, submandibular glands of patients 
with SS have a lower volume and increased parenchymal heterogenicity compared with 
normal individuals. Receiver operating characteristic (ROC) curve analyses showed that 
these findings could reliably discriminate patients from healthy individuals (specificity 
>90%), but could detect only one-half of patients with SS (sensitivity 48–64%). Detection of 
hypoechoic areas, echogenic streaks, cysts and irregular gland margins are highly 
suggestive of SS (Takagi et al., 2010). 
Similarly, parotid MRI can also prove to be an adjunct diagnostic tool to detect 
heterogeneity in the salivary glands and specific cystic lésions (Roberts et al., 2008). Niemela 
et al. recently showed that magnetic resonance sialography was the most sensitive method 
for detecting glandular changes (96%), followed by MRI (81%) and ultrasonography 
(78%)(Niemela et al., 2001). However, the changes detected did not correlate with saliva 
secretion, whereas the focus scores the intensity of lymphocytic infiltration in salivary gland 
biopsy specimens were related only to parotid MRI findings (Niemela et al., 2004). 
The involvement of epigenetic mechanisms in disease processes were established when 
DNA methylation was first identified as an important factor in tumor biology. Nevertheless, 
impaired epigenetic control has been linked to various autoimmune diseases including 
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and SS ((Pan & 
Sawalha, 2009; Richardson, 2007). In salivary glands from SS patients undergoing 
extracellular matrix remodelling, mechanotransduction may affect epigenetic control of 
gene expression (Gonzalez et al., 2011a). Global DNA methylation of salivary glands from 
SS patients appears to be decreased, while specific genes appear to be hypermethylated (i.e: 
BP230) (Gonzalez et al., 2011b). Over-expression of 2 miRNAs (miR-574 and miR-768-3p) 
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also contributes to the epigenetic control of gene expression in salivary glands from SS 
patients (Alevizos et al., 2011). These two micro-RNAs were associated with high degree 
inflammation and correlated with the histological focus score. Moreover, the distinctive 
signatures of these micro-RNA’s could also distinguish SS patients from normal healthy 
controls (Alevizos & Illei, 2010). As such, they could represent future diagnostic and 
prognostic biomarkers of inflammation in SS patients. 
4.7 Diagnosis and classification criteria for SS 
SS is a complex autoimmune disease with protean nonspecific features, thereby hampering 
the diagnostic process. 
Because of this, many patients often remain either under diagnosed or diagnosis is made 
after a long lapse of time when full-fledged symptoms are obvious. The seminal importance 
of making an early diagnosis relies on the fact that appropriate treatment can be tailored 
and proper management of patients set down. Actually, there are no definite diagnostic 
criteria for SS and diagnosis is essentially based on the clinical insights of the experienced 
physician in the light of a set of biological and clinical manifestations. Even if classification 
criteria have been established for SS, they do not have a sensitivity and specificity of 100%, 
and therefore cannot be used as diagnostic criteria. As a general rule, classification criteria 
are used as diagnostic criteria in clinical studies in order to standardize diagnosis for 
patients participating in multicenter clinical studies and therefore enable analysis of data in 
an unbiased fashion, or for teaching purposes. The stumbling block for devising diagnostic 
criteria for SS as in other autoimmune diseases is the temporal progression of the clinical 
manifestations. In very early disease, the clinical manifestations are not overt, thereby 
fostering further hurdles in the adequate diagnosis. 
In 2002, an American–European consensus group was created and a new set of classification 
criteria for SS has been proposed (Table 2) (Vitali et al., 2002). These criteria comprise 
subjective criteria: ocular symptoms and oral symptoms, and objective criteria: ocular signs, 
histopathological signs (focus score ≥ 1), oral signs, and serological signs (presence of 
antinuclear antibodies: anti-SSA or anti-SSB). Patients are classified as SS if 4 of the 6 
mentioned criteria are present, as long as histopathology or serology is positive, or if 3 of 
any 4 objective criteria are present.  
1. Ocular symptoms 
Ocular symptoms are present if there is a positive answer to at least one of the 
following questions: 
 Have you had daily persistent, troublesome dry eyes for >3 months? 
 Do you have recurrent sensation of sand or gravel in the eyes? 
 Do you use tear substitutes > 3times daily? 
       
2. Oral symptoms  
Oral symptoms are present if there is a positive response to at least one of the 
following questions: 
 Do you have a daily feeling of dry mouth > 3 months? 
 Have you had recurrent or persistent swollen salivary glands as an adult? 
 Do you drink frequently liquids to help in swallowing dry food? 
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3. Objective evidence of ocular involvement as defined by a positive result for at least 
one of the following tests: 
 Positive Schirmer’s test without anesthesia (5mm) 
 Rose Bengal or other ocular dye staining score (4 according to Van Bijsterveld’s 
scoring system) 
4. Histopathology 
 Focal lymphocyte sialoadenitis in minor salivary glands, evaluated by an expert 
histopathologist, with a focus score  1 (defined as a number of lymphocytic foci 
that are adjacent to normal appearing mucous acini and contain more than 50 
lymphocytes per 4mm2 of glandular tissue 
5. Objective evidence of salivary gland involvement defined as positive result of at least 
one of the following diagnostic tests: 
 Parotid sialography showing the presence of diffuse sialectasis (punctuate, 
cavitary or destructive pattern) without evidence of obstruction of major 
salivary ducts 
 Salivary scintigraphy showing delayed uptake, reduced concentration and/or 
delayed excretion of tracer 
6. Presence of autoantibodies to Ro/SSA or La/SSB, or both, in the serum. 
Exclusion Criteria 
 Past head and neck radiation treatment 
 Hepatitis C or HIV infection 
 Pre-existing lymphoma 
 Sarcoidosis 
 Graft versus host disease 
 Use of anticholinergic drugs 
Classification of Primary and secondary Sjögren’s syndrome 
In the absence of any underlying disease, primary Sjögren’s syndrome is defined as the 
presence of any four diagnostic criteria as long as either item4 (histopathology) or 
6(serologic autoantibody) is positive or as the presence of any 3 of the 4 objective criteria 
items (items 3,4,5,6). 
In the presence of any potentially associated disease (such as another autoimmune 
disease; systemic lupus erythematosus for example)), the presence of item 1or 2 plus any 
other 2 items 3,4 and 5 might be suggestive of secondary Sjögren’s disease. 
Table 2. American-European classification criteria for SS 
4.8 Differential diagnosis of SS 
The differential diagnosis of SS includes diseases that present with sicca symptoms and 
parotid gland enlargement. Sarcoidosis can mimic SS, but salivary gland biopsy usually 
depicts non-caseating granuloma and autoantibodies are absent and clinical features such as 
hilar lymphadenopathy, uveitis or hypercalcemia are more suggestive of sarcoidosis 
(Ramos-Casals et al., 2004). Other medical conditions masquerading as SS include 
lipoproteinemias (types II, IV and V), chronic graft-versus-host disease, amyloidosis, and 
infection with viruses such as human immunodeficiency virus (HIV), human T-lymphocytic 
virus-I (HTLV-I) and HCV. Patients with HIV infection may present with sicca 
manifestations, parotid gland enlargement, pulmonary involvement, and lymphadenopathy. 
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These patients have an increased prevalence of HLA-DR5 alloantigen (Itescu et al., 1990). 
The two diseases can easily be distinguished, as patients with HIV infection are usually 
young males, have no autoantibodies to Ro (SS-A) and La (SS-B), and the lymphocytic 
infiltrates of the salivary glands consist of CD8+ T cells. HCV can produce a chronic 
lymphocytic sialadenitis that ressembles SS (Haddad et al., 1992). These patients have a 
higher mean age, a lower prevalence of parotid gland enlargement and a higher prevalence 
of liver involvement than patients with pSS. However, patients with SS do not possess an 
increased frequency of antibodies to HCV in their sera. In cases with isolated dry mouth or 
dry eyes, other potential causes including deficiency disorders (vitamin A deficiency  
for example), drugs, infections, endocrinopathies, or degenerative diseases should be 
excluded. 
4.9 Measuring disease activity in SS 
In an attempt to provide tools to assess pSS patients in clinical practice as well as in 
therapeutic trials, several disease activity indices have been designed. These include the 
SSDAI (SS Disease Activity Index), SCAI (Sjögren’s Systemic Clinical Activity Index) and 
ESSDAI (EULAR SS Disease Activity Index). SSDAI and ESSDAI are global scores. SCAI is 
a composite score. Validity is a limitation for SSDAI and SCAI (Campar & Isenberg, 2010). 
ESSDAI is complemented by ESSPRI for the assessment of subjective features. It is more 
accurate in detecting changes in activity. Comparing the three disease activity indices, it 
was observed that for patients with improved activity, the 3 disease activity indices 
showed similar, large sensitivity to change. However, the ESSDAI seemed to detect 
changes in activity more accurately than other disease activity indexes. Notably, for 
patients with stable activity, the ESSDAI did not show erroneous improvement (Seror et 
al., 2010). The ESSDAI consists of 12 organ-specific domains, which are predominantly 
clinical; only 2 of them include haematological (cytopenias) or biological (clonal 
component, serum complement levels, serum IgG and cryoglobulins) findings (Seror et 
al., 2010). For each domain, features of disease activity were classified in 3 or 4 levels 
according to their severity (Table 3). 
Domain Activity 
level 
Description 
Constitutional 0-2 0=no symptoms; 1=mild fever and 5-10% weight 
loss; 2=severe fever and >10% weight loss 
Lymphadenopathy 0-3 0= absence of the following features; 1=Lymphadenopathy 
≥ 1 cm in any nodal region or ≥ 2 cm in inguinal 
region; 2=Lymphadenopathy ≥ 2 cm in any nodal region or 
≥ 3 cm in inguinal region, and/or splenomegaly (clinically 
palpable or assessed by imaging); 3=Current malignant B-
cell proliferative disorder 
Glandular 0-2 0=no glandular swelling; 1=Small glandular swelling with 
enlarged parotid (≤ 3 cm), or limited submandibular or 
lachrymal swelling; 2=Major glandular swelling with 
enlarged parotid (> 3 cm), or important submandibular or 
lachrymal swelling 
www.intechopen.com
 
Insights and Perspectives in Rheumatology 
 
138 
Domain Activity 
level 
Description 
Articular 0-3 0= no articular symptoms; 1=Arthralgias in hands, wrists, 
ankles and feet accompanied by morning stiffness (>30 
min); 2=1 to 5 (of 28 total count) synovitis; 3=≥ 6 (of 28 total 
count) synovitis. 
Cutaneous 0-3 0=absence of active cutaneous involvement; 1=Erythema 
multiforma; 2=Limited cutaneous vasculitis, including 
urticarial vasculitis, or purpura limited to feet and ankle, or 
subacute cutaneous lupus; 3=Diffuse cutaneous vasculitis, 
including urticarial vasculitis, or diffuse purpura, or ulcers 
related to vasculitis 
Pulmonary 0-3 0=absence of active pulmonary involvement; 1= Persistent 
cough or bronchial involvement with no radiographic 
abnormalities on radiography Or radiological or HRCT 
evidence of interstitial lung disease with: No breathlessness 
and normal lung function test; 2=Moderately active 
pulmonary involvement, such as interstitial lung disease 
shown by HRCT with shortness of breath on exercise 
(NHYA II) or abnormal lung function tests restricted to: 
70% >DLCO≥ 40% or 80%>FVC≥60%; 3=Highly active 
pulmonary involvement, such as interstitial lung disease 
shown by HRCT with shortness of breath at rest (NHYA 
III, IV) or with abnormal lung function tests: DLCO< 40% or 
FVC< 60%. 
 
Renal 0-3 0=Absence of currently active renal involvement with 
proteinuria< 0.5 g/d, no hematuria, no leucocyturia, no 
acidosis, or long-lasting stable proteinuria due to 
damage; 1=Evidence of mild active renal involvement, 
limited to tubular acidosis without renal failure or 
glomerular involvement with proteinuria (between 0.5 and 
1 g/d) and without hematuria or renal failure (GFR ≥60 
ml/min); 2=Moderately active renal involvement, such as 
tubular acidosis with renal failure (GFR <60 ml/min) or 
glomerular involvement with proteinuria between 1 and 
1.5 g/d and without hematuria or renal failure (GFR ≥60 
ml/min) or histological evidence of extra-membranous 
glomerulonephritis or important interstitial lymphoid 
infiltrate; 3=Highly active renal involvement, such as 
glomerular involvement with proteinuria >1.5 g/d or 
hematuria or renal failure (GFR <60 ml/min), or 
histological evidence of proliferative glomerulonephritis or 
cryoglobulinemia related renal involvement 
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Domain Activity 
level 
Description 
Muscular 0-3 0= absence of muscular involvement; 1=Mild active 
myositis shown by abnormal EMG or biopsy with no 
weakness and creatine kinase (N <CK ≤ 2N); 2=Moderately 
active myositis proven by abnormal EMG or biopsy with 
weakness (maximal deficit of 4/5), or elevated creatine 
kinase (2N<CK ≤4N); 3=Highly active myositis shown by 
abnormal EMG or biopsy with weakness (deficit ≤ 3/5) or 
elevated creatine kinase (>4N) 
 
 
PNS 0-3 0 = absence of PNS involvement; 1=Mild active peripheral 
nervous system involvement, such as pure sensory axonal 
polyneuropathy shown by NCS or trigeminal (V) 
neuralgia; 2= Moderately active peripheral nervous 
system involvement shown by NCS, such as axonal 
sensory-motor neuropathy with maximal motor deficit of 
4/5, pure sensory neuropathy with presence of 
cryoglobulinemic vasculitis, ganglionopathy with 
symptoms restricted to mild/moderate ataxia, 
inflammatory demyelinating polyneuropathy (CIDP) with 
mild functional impairment (maximal motor deficit of 
4/5or mild ataxia),Or cranial nerve involvement of 
peripheral origin (except trigeminal (V) 
neuralgia) ;3=Highly active PNS involvement shown by 
NCS, such as axonal sensory-motor neuropathy with 
motor deficit ≤3/5, peripheral nerve involvement due to 
vasculitis (mononeuritis multiplex etc.), severe ataxia due 
to ganglionopathy, inflammatory demyelinating 
polyneuropathy (CIDP) with severe functional 
impairment: motor deficit ≤3/5 or severe ataxia 
 
 
CNS 0-3 0= absence of CNS involvement; 1=Moderately active CNS 
features, such as cranial nerve involvement of central 
origin, optic neuritis or multiple sclerosis-like syndrome 
with symptoms restricted to pure sensory impairment or 
proven cognitive impairment; 3=Highly active CNS 
features, such as cerebral vasculitis with cerebrovascular 
accident or transient ischemic attack, seizures, transverse 
myelitis, lymphocytic meningitis, multiple sclerosis-like 
syndrome with motor deficit. 
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Domain Activity 
level 
Description 
Hematological 0-3 0=absence of autoimmune cytopenia; 1=Cytopenia of auto-
immune origin with neutropenia (1000 < neutrophils < 
1500/mm3), and/or anemia (10 < hemoglobin < 12 g/dl), 
and/or thrombocytopenia (100,000 < platelets < 
150,000/mm3) Or lymphopenia (500 < lymphocytes < 
1000/mm3); 2= Cytopenia of auto-immune origin with 
neutropenia (500 ≤ neutrophils ≤ 1000/mm3), and/or 
anemia (8 ≤ hemoglobin ≤ 10 g/dl), and/or 
thrombocytopenia (50,000 ≤ platelets ≤ 100,000/mm3) Or 
lymphopenia (≤500/mm3) ;3=Cytopenia of auto-immune 
origin with neutropenia (neutrophils < 500/mm3), and/or 
or anemia (hemoglobin < 8 g/dl) and/or 
thrombocytopenia (platelets <50,000/mm3 
Biological 0-2 0=absence of any of the following biological feature; 
1=Clonal component and/or hypocomplementemia (low 
C4 or C3 or CH50) and/or hypergammaglobulinemia or 
high IgG level between 16 and 20 g/L; 2=Presence of 
cryoglobulinemia and/or hypergammaglobulinemia or 
high IgG level > 20 g/L, and/or recent onset 
hypogammaglobulinemia or recent decrease of IgG level 
(<5 g/L) 
 
Table 3. ESSDAI index for measuring disease activity in SS (modified according to Seror et 
al., 2010) 
4.10 Biological markers of disease activity in SS 
Biological biomarkers are of pivotal importance in determining which patients are at risks of 
developing systemic complications of SS and those who could benefit from therapeutic 
immunomodulation. Classical markers of inflammation such as C-reactive protein and 
erythrocyte sedimentation rate are of limited value to assess disease activity in SS. These 
past ten years, significant progress has been made in deciphering the molecular mechanisms 
underscoring the pathogenesis of SS. As such, the pivotal role of B-cell in pathophysiology 
of SS has been unearthed (Groom et al., 2002, Gottenberg et al., 2006, Mackay et al., 2007). 
The B-cell activating factor (BAFF) is significantly increased in the sera and in the salivary 
glands of pSS patients (Mariette et al., 2003, Lavie et al., 2004). BAFF levels in the sera of pSS 
patients correlate with the presence of anti-SSA autoantibodies and with the ESSDAI index. 
Serum beta macroglobulin, another marker of B lymphocyte activation, has been shown to 
be useful marker of disease activity in pSS, in that it correlated with the presence of disease 
flare as well as with the occurrence of extraglandular manifestations (Gottenberg et al., 
2005). More recently, the levels of serum beta-microglobulin have been observed to correlate 
with the ESSDAI index (Pertovaara & Korpela, 2011). Serum free light chains have also been 
detected to be increased in pSS patients and shown to correlate with disease activity 
(Gottenberg et al., 2007). Several studies are ongoing to evaluate other biomarkers of disease 
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activity of pSS such as chemokines induced by interferon pathway and IL-21, and also other 
markers of B-cell activation are being currently investigated. 
5. Prognostic features of SS 
Much knowledge has been gathered these last ten years about the outcome of patients with 
SS. Although not a benign disease, primary SS has a slow insidious progression with no 
rapid deterioration in salivary gland function, systemic markers or dramatic changes in 
clinical manifestations (Gannot et al., 2000). Primary SS, as such is a relatively chronic stable 
condition, with only mild deterioration of main disease characteristics (Theander et al., 
2005). Significant loss of glandular function and quality of life are highlighted during the 
first years of disease (median of 6 years) and remain stable afterwards. The presence of 
immunological abnormalities such as the presence of anti-SSA autoantibodies, 
hypocomplementemia, increased levels of IgG, high focus scores and low unstimulated 
whole saliva, is associated with more severe glandular dysfunction (Haldorsen et al., 2008), 
Theander et al., 2005, Pijpe et al. 2007). It has to be underlined that even if the clinical course 
of the disease is usually stable, similarly to other autoimmune diseases, individual patients 
might present some flares and remissions. However, there are two exceptions to this 
classical benign course, which include a high incidence of lymphoma and the development 
of systemic manifestations, pertaining to a worsened prognostic significance. The presence 
of autoantibodies is correlated with the number of systemic manifestations and more 
specifically anti-SSA autoantibodies are the strongest predictors of extra-glandular 
manifestations (Ter Borg et al., 2011). Furthermore, serum free light chains and serum 2 
microglobulin are increased and correlate with extra-glandular involvement in pSS 
(Gottenberg et al., 2007; Gottenberg et al., 2005). These findings reflect that enhanced 
disturbance of the immune system portrayed by B-cell hyperactivity with 
hypergammaglobulinemia and autoantibody formation, is associated with systemic 
manifestations in primary SS. A steady clinical course is usually observed in patients with 
peri-epithelial lesions (tubulointerstitial nephritis, lung and liver involvement), while those 
presenting with extra-epithelial lesions such as polyneuropathy, vasculitis, 
glomerulonephritis, purpura and vasculitis, have increased morbidity and mortality 
(Skopouli et al., 2000, Ioannidis et al., 2002). The cardinal role of cryoglobulinemia has been 
underlined in this latter group of patients as being the harbinger of the extraepithelial 
manifestations. These extraepithelial characteristics are associated with a high risk of 
developing life-threatening conditions and require tailoring treatment with higher doses of 
corticosteroids and immunosuppressive agents. On the other hand, in patients presenting 
with peri-epithelial lesions, treatment requires less use of steroids and immunosuppressive 
drugs and a less frequent clinical monitoring is recommended.  
Several reports have noted an increased incidence of malignant non-Hodgkin lymphomas 
(NHL) in SS patients, with an estimated risk of up to 44 times greater as compared to 
general population (Kassan et al., 1978). This risk increases with disease duration, is 
maintained with time and is not related to the patient age at time of diagnosis of pSS 
(Solans-Laque et al., 2011). Several predictors of lymphoma development have been detailed 
and include anemia, lymphadenopathy, lymphopenia, hypocomplementemia, peripheral 
neuropathy, cutaneous vasculitis, bilateral parotid gland swelling, severe involvement in 
parotid scintigraphy, and cryoglobulinemia (Voulgarelis, Dafni, Isenberg, & Moutsopoulos, 
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1999), (Brito-Zeron et al., 2007). It has been observed that patients with two of three 
following factors (parotid scintigraphy, vasculitis, hypocomplementemia) were associated 
with a lower survival as compared to patients with no factor. More recently, 
hypocomplementemia and lymphocytopenia were independent risk factors for developing 
lymphoma but only hypocomplementemia was related to earlier development of NHL and 
higher mortality ((Brito-Zeron et al., 2007; Solans-Laque et al., 2011). Furthermore, it has 
been also observed that the detection of germinal center-like lesions in pSS diagnostic 
salivary biopsies is a highly predictive marker of NHL (Theander et al., 2011). Patients with 
high-to-intermediated grade lymphoma have significantly worse survival while large tumor 
diameters and the presence of B symptoms are additional risk factors for increased mortality 
(Voulgarelis et al., 1999). 
6. Conclusions 
SS is a chronic autoimmune disease characterized by glandular and systemic manifestations. 
Because of the increased risk of developing lymphoma in pSS patients, making the diagnosis 
of SS is of pivotal importance. The herald of newer diagnostic tools could help clinicians and 
thereby provide significant relief to patients through earlier treatments. Deciphering 
mechanistic processes inherent to the pathophysiology of SS should in the future provide 
more sophisticated means for early diagnosis of SS. 
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